Literature DB >> 8719303

GH responsiveness to repeated GHRH or hexarelin administration in normal adults.

A Sartorio1, A Conti, S Ferrero, A Spada, G Faglia.   

Abstract

GH responses, calculated as the net incremental area under the curve (GH nAUC/h), to two consecutive 1 microgram/kg/bw iv GHRH boluses (administered at 0 and 120 min, test a), to one 1 microgram/kg/bw iv GHRH bolus followed by a 1 microgram/kg/bw iv hexarelin bolus (administered at 0 and 120 min respectively, test b) and to two consecutive 1 microgram/kg/bw iv hexarelin boluses (administered at 0 and 120 min, test c) were evaluated in 6 normal adults. The first GHRH injection caused a clear rise in serum GH levels in all subjects (mean GH nAUC/h, test a: 832.1 +/- 59.4 ng/ml/h, range: 723.7-1074.0 ng/ml/h; test b: 859.2 +/- 122.9 ng/ml/h, range 618.0-1422.7 ng/ml/h). Hexarelin administration elicited a marked GH release (test c: 1424 +/- 208.2 ng/ml/h, range: 810.0-2154.0 ng/ml/h), which was significantly higher than those observed after GHRH (vs test a: p < 0.02, vs test b: p < 0.05). After the first GHRH bolus, the second GHRH injection (test a) was unable to sustain GH elevated levels (mean GH nAUC: 74.5 +/- 26.5 ng/ml/h, range: 9.7-182.2 ng/ml/h), while hexarelin administration (test b) caused a clear GH rise in all subjects (GH nAUC: 1049.7 +/- 105.2 ng/ml/h, range: 786.0-1356.0 ng/ml/h). Repeated hexarelin administration (test c) was associated with a significant (p < 0.02) reduction of GH responses to the second bolus (286.6 +/- 43.1 ng/ml/h), which were however significantly higher than those observed after the second GHRH bolus (p < 0.05). In conclusion, these results demonstrate that repeated hexarelin administration causes a reduction of GH responsiveness, which is less marked than that induced by repeated GHRH administration, probably due to the more potent GH-releasing effect of hexarelin. Moreover, when administered after GHRH, hexarelin has a sustained GH-releasing effect in contrast to the poor efficacy of GHRH, thus suggesting that the acute effect of hexarelin is probably not mediated through hypothalamic GHRH pathways.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8719303     DOI: 10.1007/BF03349794

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  28 in total

1.  Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites.

Authors:  E E Codd; A Y Shu; R F Walker
Journal:  Neuropharmacology       Date:  1989-10       Impact factor: 5.250

2.  Repeated GH-releasing hormone administration unravels different GH secretory patterns in normal adults and children.

Authors:  E Ghigo; S Goffi; E Mazza; E Arvat; M Procopio; J Bellone; E E Müller; F Camanni
Journal:  Acta Endocrinol (Copenh)       Date:  1989-05

3.  A study on the regulation of growth hormone release from the pituitaries of rats in vitro.

Authors:  C Y Bowers; G A Reynolds; D Chang; A Hong; K Chang; F Momany
Journal:  Endocrinology       Date:  1981-03       Impact factor: 4.736

4.  Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites.

Authors:  A D Blake; R G Smith
Journal:  J Endocrinol       Date:  1991-04       Impact factor: 4.286

5.  Chronic exposure of cultured rat anterior pituitary cells to GRF causes partial loss of responsiveness to GRF.

Authors:  L M Bilezikjian; W W Vale
Journal:  Endocrinology       Date:  1984-11       Impact factor: 4.736

6.  On the actions of the growth hormone-releasing hexapeptide, GHRP.

Authors:  C Y Bowers; A O Sartor; G A Reynolds; T M Badger
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

7.  Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation.

Authors:  W K DeBell; S S Pezzoli; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1991-06       Impact factor: 5.958

8.  Human pancreatic tumor growth hormone-releasing factor: dose-response relationships in normal man.

Authors:  M L Vance; J L Borges; D L Kaiser; W S Evans; R Furlanetto; J L Thominet; L A Frohman; A D Rogol; R M MacLeod; S Bloom
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

9.  Growth hormone-releasing peptide and its analogues Novel stimuli to growth hormone release.

Authors:  M Korbonits; A B Grossman
Journal:  Trends Endocrinol Metab       Date:  1995-03       Impact factor: 12.015

10.  Parallel studies of His-DTrp-Ala-Trp-DPhe-Lys-NH2 and human pancreatic growth hormone-releasing factor-44-NH2 in rat primary pituitary cell monolayer culture.

Authors:  O Sartor; C Y Bowers; D Chang
Journal:  Endocrinology       Date:  1985-03       Impact factor: 4.736

View more
  1 in total

1.  GH responses to two consecutive bouts of respiratory muscle endurance training in healthy adults.

Authors:  A Sartorio; F Agosti; A Patrizi; G Tringali; N Marazzi; M Giunta; E E Muller; A E Rigamonti
Journal:  J Endocrinol Invest       Date:  2012-07-24       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.